This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Il Dong Pharmaceutical Co., Ltd.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Myongjae Lee: Innovator in CFTR Modulation
Introduction
Myongjae Lee is a notable inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate the cystic fibrosis transmembrane conductance regulator (CFTR).
Latest Patents
Myongjae Lee holds a patent for "Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators." This patent provides CFTR modulator and phosphodiesterase 4 (PDE4) inhibitor compounds, which can be utilized for treating eye diseases and CFTR-related indications. The patent also outlines methods for using these compounds to inhibit PDE4 in biological systems, addressing inflammatory diseases and other related conditions.
Career Highlights
Myongjae Lee is associated with Il Dong Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on developing effective treatments that can improve patient outcomes in various medical conditions.
Collaborations
He collaborates with talented individuals such as Changmok Oh and Dami Lim, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Myongjae Lee's contributions to CFTR modulation and his ongoing work at Il Dong Pharmaceutical Co., Ltd. highlight his role as a key inventor in the pharmaceutical industry. His innovative approaches are paving the way for new treatments and therapies.